Ray Prudo, M.D. 13D/13G Filings for Akari Therapeutics, Plc (AKTX)

Ray Prudo, M.D. 13D and 13G filings for Akari Therapeutics, Plc:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2025-02-14
5:00 pm
Purchase
2024-11-1413DAkari Therapeutics, Plc
AKTX
Ray Prudo, M.D.4,926,600,800
9.300%
4,926,600,800increase
(New Position)
Filing